Search
Jupiter Neurosciences Inc
JUNSAdd to Watchlist
0.223USD
+0.008+3.72%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
8.09MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.72%
5 Days
-20.36%
1 Month
-12.55%
6 Months
-77.92%
Year to Date
-78.14%
1 Year
-86.48%
Key Figures
0.222Open
0.227High
1.51MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
4.17%Turnover Ratio
0.215Prev. Close
0.212Low
210.83KTurnover
LossP/E Static
-2.91P/B
0.00%Div Yield TTM
-205.98%ROA
3.33052wk High
0.41Volume Ratio
-2.44MNet Profit
36.28MShares
-0.2620EPS TTM
--Beta
-6529.17%ROE
0.17252wk Low
6.65%Amplitude
76.61%Gross Margin
8.09MMarket Cap
-2.05Reward/Risk
7.66%Risk Rate
TradingKey Stock Score of Jupiter Neurosciences Inc
Currency: USD Updated: 2026-07-02Key Insights
Jupiter Neurosciences Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 229 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Jupiter Neurosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Jupiter Neurosciences Inc Highlights
StrengthsRisks
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Growing
The company is in a growing phase, with the latest annual income totaling USD 21.80K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 21.80K.
Overvalued
The company’s latest PE is -0.85, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.06M shares, increasing 42.85% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
25.000
Target Price
0.00%
Upside Space
Jupiter Neurosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Jupiter Neurosciences Inc Info
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Ticker SymbolJUNS
CompanyJupiter Neurosciences Inc
CEORosen (Christer)
Websitehttps://jupiterneurosciences.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Jupiter Neurosciences Inc (JUNS)?
The current price of Jupiter Neurosciences Inc (JUNS) is 0.22.
What is the symbol of Jupiter Neurosciences Inc?
The ticker symbol of Jupiter Neurosciences Inc is JUNS.
What is the 52-week high of Jupiter Neurosciences Inc?
The 52-week high of Jupiter Neurosciences Inc is 3.33.
What is the 52-week low of Jupiter Neurosciences Inc?
The 52-week low of Jupiter Neurosciences Inc is 0.17.
What is the market capitalization of Jupiter Neurosciences Inc?
The market capitalization of Jupiter Neurosciences Inc is 8.09M.
Is Jupiter Neurosciences Inc (JUNS) currently rated as Buy, Hold, or Sell?
According to analysts, Jupiter Neurosciences Inc (JUNS) has an overall rating of Buy, with a price target of 25.00.
What is the Earnings Per Share (EPS TTM) of Jupiter Neurosciences Inc (JUNS)?
The Earnings Per Share (EPS TTM) of Jupiter Neurosciences Inc (JUNS) is -0.25.